Acetaminophen
Aspirin
Ibuprofen
Indomethacin

Antiandrogens⏵

All
Proxalutamide
Spironolactone

Antihistamines⏵

All H1RAs
Azelastine
Famotidine

Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin

Diet
Exercise
Sleep
Sun

Melatonin
Metformin

Adintrevimab
Amubarvimab/romlusevimab
BMS mAbs
Bamlanivimab/etesevimab
Bebtelovimab
Casirivimab/imdevimab
Pemivibart
Ravulizumab
Regdanvimab
SA58
Sarilumab
Sipavibart
Sotrovimab
Tixagevimab/cilgavimab
Vilobelimab

Mpro inhibitors⏵

Atilotrelvir
Ensitrelvir
Ibuzatrelvir
Leritrelvir
Lufotrelvir
Olgotrelvir
Paxlovid
Pomotrelvir
Xiannuoxin

Naso/orophar..⏵

Alkalinization
Cetylpyridinium Chloride
Chlorhexidine
Chlorpheniramine
HH-120
Hydrogen Peroxide
Iota-carrageenan
NaCl
Nitric Oxide
Phthalocyanine
Povidone-Iodine
Sodium Bicarbonate

Nigella Sativa
Nitazoxanide
PPIs
Quercetin

RdRp inhibitors⏵

Azvudine
Bemnifosbuvir
Deuremidevir
Favipiravir
Molnupiravir
Remdesivir

TMPRSS2 inh.⏵

All
Bromhexine
Camostat
Nafamostat

Vitamin A
Vitamin B9
Vitamin B12
Vitamin C
Vitamin D
Vitamin K

Andrographolide
Artemisinin
Cannabidiol
Dexamethasone
Ensovibep
Lactoferrin
Lopinavir/ritonavir
Losartan
Masks
Montelukast
N-acetylcysteine
Niclosamide
Peginterferon Lambda
Probiotics
Propolis
Resveratrol
Tocilizumab
Ursodeoxycholic acid

Other
Feedback
Home

..

All molnupiravir studies

..

..

←

next
study

→

previous
study

c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)

Acetaminophen	Meta
Aspirin	Meta
Ibuprofen	Meta
Indomethacin	Meta
Close

Selenium	Meta
Zinc	Meta
Close

Antiandrogens⏵

All	Meta
Proxalutamide	Meta
Spironolactone	Meta
Close

Antihistamines⏵

All H1RAs	Meta
Azelastine	Meta
Famotidine	Meta
Close

Mpro inhibitors⏵

Atilotrelvir	Meta
Ensitrelvir	Meta
Ibuzatrelvir	Meta
Leritrelvir	Meta
Lufotrelvir	Meta
Olgotrelvir	Meta
Paxlovid	Meta
Pomotrelvir	Meta
Xiannuoxin	Meta
Close

Naso/orophar..⏵

RdRp inhibitors⏵

Azvudine	Meta
Bemnifosbuvir	Meta
Deuremidevir	Meta
Favipiravir	Meta
Molnupiravir	Meta
Remdesivir	Meta
Close

TMPRSS2 inh.⏵

All	Meta
Bromhexine	Meta
Camostat	Meta
Nafamostat	Meta
Close

Diet	Meta
Exercise	Meta
Sleep	Meta
Sun	Meta
Close

Vitamin A	Meta
Vitamin B9	Meta
Vitamin B12	Meta
Vitamin C	Meta
Vitamin D	Meta
Vitamin K	Meta
Close

Home Adoption Other Treatments

Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19

Reuters, Oct 2021

https://c19early.org/mp5424.html

Trial CTRI/2021/08/035424 for moderate condition patients has been reported as terminated for futility. Results are not available yet1.

Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity2-16. Multiple analyses have identified variants potentially created by molnupiravir17-21.

Important missing comments or errors? Let us know.

1. trialsearch.who.int, trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/08/035424.

2. Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.science.org, doi.org.

3. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

4. Shum, C., An investigational study into the drug-associated mutational signature in SARS-CoV-2 viruses, The University of Hong Kong, PhD Thesis, hub.hku.hk/handle/10722/344396hku.hk.

5. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

6. Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40bhawaii.edu.

7. Huntsman (B) et al., Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays, Toxicological Sciences, doi:10.1093/toxsci/kfaf093.oup.com, doi.org.

8. Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.sciencedirect.com, doi.org.

9. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

10. Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.wiley.com, doi.org.

11. Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.sciencedirect.com, doi.org.

12. Rahman, M., Elucidation of the DNA repair mechanisms involved in the repair of DNA damage caused by the Arabinosides and Anti-COVID-19 drugs, tokyo-metro-u.repo.nii.ac.jp/records/2000972ac.jp.

13. Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.oup.com, doi.org.

14. Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448asianmedjam.com.

15. Standing et al., Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients, Nature Communications, doi:10.1038/s41467-024-45641-0.nature.com, doi.org.

16. Mori et al., Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N4-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir, Free Radical Research, doi:10.1080/10715762.2025.2469738.tandfonline.com, doi.org.

17. Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.karger.com, doi.org.

18. Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.nature.com, doi.org.

19. Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.sciencedirect.com, doi.org.

20. Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.nature.com, doi.org.

21. twitter.com, twitter.com/LongDesertTrain/status/1597353291868155906.

Reuters et al., 9 Oct 2021, Randomized Controlled Trial, India, preprint, 1 author.

This Paper Molnupiravir All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Public domain CC0 1.0